From: Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
Involvement
Incidence
Simple pattern
One lobe or two adjacent lobes
20–25%
Complex pattern
Primarily one lobe and smaller satellites contralaterally
10–15%
Diffuse pattern
Multifocal disease
60–70%